New shared care guidelines on PIP

New shared care guidelines on PIP

Shared care guidelines on atomoxetine, methylphenidate, methylphenidate MR, guanfacine and lisdexamphetamine for the management of ADHD have been produced by CAMHs and approved by APC. These guidelines have been produced to support the seamless transfer of prescribing and patient monitoring from secondary to primary care and provides an information resource to support clinicians providing care to the patient. These guidelines are underpinned by the Portsmouth and South East Hampshire Area Prescribing Committee Shared Care Agreement: Licensed ADHD Medications for the Treatment of Childhood ADHD for Fareham & Gosport and South East Hampshire Patients. The shared care guidelines can be accessed via the following PIP link:

A shared care guideline on Sativex spray has been developed and approved by DPC and accepted for use by APC. The guideline supports the transfer of care for people with moderate to severe


This site has been created on behalf of Hampshire and Isle of Wight general practice. It aims to provide a single place to access all the COVID-19 information and guidance needed to ensure safe, effective care for patients whilst ensuring the safety and wellbeing of staff and the resilience of practices.

Contact us

Hampshire, Southampton and Isle of Wight Clinical Commissioning Group

Commissioning House, Fort Southwick, James Callaghan Drive, Fareham, Hampshire, PO17 6AR